MyD88-dependent BCG immunotherapy reduces tumor and regulates tumor microenvironment in bladder cancer murine model

Bacillus Calmette-Guerin (BCG) is the only FDA approved first line therapy for patients with nonmuscle invasive bladder cancer. The purpose of this study is to better understand the role of innate immune pathways involved in BCG immunotherapy against murine bladder tumor. We first characterized the...

Descripción completa

Detalles Bibliográficos
Autores principales: de Queiroz, Nina M. G. P., Marinho, Fabio V., de Araujo, Ana Carolina V. S. C., Fahel, Julia S., Oliveira, Sergio C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329301/
https://www.ncbi.nlm.nih.gov/pubmed/34341449
http://dx.doi.org/10.1038/s41598-021-95157-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329301/
https://www.ncbi.nlm.nih.gov/pubmed/34341449
http://dx.doi.org/10.1038/s41598-021-95157-6

Ejemplares similares